To determine whether zidovudine, administered to reduce vertical transmission of human immunodeficiency virus type 1 (HIV-1), impacts the level of maternal viral DNA within the lymphocytes of infected pregnant women.
A prospective, nonrandomized study of 42 HIV-1 infected pregnant women.
Nineteen women received zidovudine therapy to reduce HIV-1 perinatal transmission, and 23 were untreated.
HIV-1 DNA was determined by polymerase chain reaction amplification of lymphocyte DNA from maternal blood samples obtained at the time of delivery.
Treated and untreated, transmitting and nontransmitting groups were compared for clinical, virologic, and immunologic parameters with a ttest or a Fisher Exact Test, and for copies of HIV-1 DNA per 106 CD4+T cells with a Mann-Whitney rank sum test.
Untreated pregnant women who transmitted HIV-1 to their infants had lower CD4+T-cell counts and a greater degree of immune complex dissociated p24 antigenemia than did the untreated nontransmitting group (p<0.01) but did not differ significantly with respect to age, race, or mode of delivery.
The level of HIV-1 proviral DNA within lymphocytes was significantly greater In the untreated transmitting group than in the nontransmitting mothers (p=0.003).
Zidovudine treatment resulted in a 78% decrease in maternal transmission (p=0.017). (...)
Mots-clés Pascal : SIDA, Virose, Infection, Virus HIV1, Virus immunodéficience humaine, Lentivirinae, Retroviridae, Virus, Immunoprophylaxie, Zidovudine, Transmission mère enfant, Prospective, Etude comparative, Virémie, Gestation, Evaluation, Femelle, Homme, Etude cohorte, Pyrimidine nucléoside, Immunopathologie, Immunodéficit, Organisation santé, Antiviral
Mots-clés Pascal anglais : AIDS, Viral disease, Infection, HIV-1 virus, Human immunodeficiency virus, Lentivirinae, Retroviridae, Virus, Immunoprophylaxis, Zidovudine, Mother to child transmission, Prospective, Comparative study, Viremia, Pregnancy, Evaluation, Female, Human, Cohort study, Pyrimidine nucleoside, Immunopathology, Immune deficiency, Public health organization, Antiviral
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0369212
Code Inist : 002B06D01. Création : 12/09/1997.